Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Merck KGaA
Bear Case (25th pct.)
-34.6% vs price
Base Case (Median)
-20.5% vs price
Bull Case (75th pct.)
-15.5% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $177.44 | 7.8% | High (40%) |
| PE Comparable | $143.73 | -12.7% | Medium (25%) |
| Growth Trajectory DCF | $110.32 | -33.0% | Medium (20%) |
| Graham Number | $104.83 | -36.3% | Medium (40%) |
| EV/EBITDA | $134.56 | -18.2% | Medium (20%) |
| EV/FCF | $130.91 | -20.5% | Medium (20%) |
| Earnings Power Value | $94.64 | -42.5% | Medium (50%) |
Based on 7 out of 7 methods, MKGAF appears overvalued at the current price of $164.58. The base case fair value of $130.91 implies 20.5% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.